Protease nexin-1 expression is altered in human breast cancer

Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international Vol. 6; no. 1; p. 16
Main Authors: Candia, Britny J, Hines, William C, Heaphy, Christopher M, Griffith, Jeffrey K, Orlando, Robert A
Format: Journal Article
Language:English
Published: England National Library of Medicine - MEDLINE Abstracts 31-05-2006
BioMed Central Ltd
BioMed Central
BMC
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread.
AbstractList Abstract Background Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. Results Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. Conclusion The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread.
BACKGROUNDUrokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. RESULTSUsing quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. CONCLUSIONThe fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread.
BACKGROUND: Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. RESULTS: Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. CONCLUSION: The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread.
Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this observation, we investigated if PN-1 is also expressed in human breast cancers where it may contribute to the regulation of uPA and participate in the development of a metastatic phenotype. Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in tissues obtained from 26 human breast tumor biopsies and compared these values with those obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly correlates with the increased expression levels found for PAI-1 and uPA. The fact that PN-1 expression is elevated in human breast cancer, and that its increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic spread.
ArticleNumber 16
Author Heaphy, Christopher M
Hines, William C
Candia, Britny J
Orlando, Robert A
Griffith, Jeffrey K
AuthorAffiliation 1 Department of Biochemistry and Molecular Biology, University of NewMexico, School of Medicine, MSC08 4670, 1 University of New Mexico, Albuquerque, New Mexico, 87131, USA
AuthorAffiliation_xml – name: 1 Department of Biochemistry and Molecular Biology, University of NewMexico, School of Medicine, MSC08 4670, 1 University of New Mexico, Albuquerque, New Mexico, 87131, USA
Author_xml – sequence: 1
  givenname: Britny J
  surname: Candia
  fullname: Candia, Britny J
  email: bcandia@unm.edu
  organization: Department of Biochemistry and Molecular Biology, University of New Mexico, School of Medicine, MSC08 4670, Albuquerque, New Mexico 87131, USA. bcandia@unm.edu
– sequence: 2
  givenname: William C
  surname: Hines
  fullname: Hines, William C
– sequence: 3
  givenname: Christopher M
  surname: Heaphy
  fullname: Heaphy, Christopher M
– sequence: 4
  givenname: Jeffrey K
  surname: Griffith
  fullname: Griffith, Jeffrey K
– sequence: 5
  givenname: Robert A
  surname: Orlando
  fullname: Orlando, Robert A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16737540$$D View this record in MEDLINE/PubMed
BookMark eNp1kktv1DAQgC1URB9w5YgiDtxSPHZiOweQqopHpUpwgLPlx6T1KmsvdlKVf4-XXZUuiJOtmc-fRzNzSo5iikjIS6DnAEq8hU72LVNCtqIF8YScPASOHt2PyWkpK0pBKkGfkWMQksu-oyfk3decZjQFm4j3IbbQ4P0mYykhxSaUxkwzZvRNiM3tsjaxsbnSc-NMdJifk6ejmQq-2J9n5PvHD98uP7fXXz5dXV5ct7bnw9yCkhRHYTgoY0YLync991x6r1A57jtmkXPDR-axPpDWeT50ijnDqJWd5Gfkauf1yaz0Joe1yT91MkH_DqR8o02eg5tQD4gC7agsOuich6HnQCkbq0p4L1l1vd-5Notdo3cY52ymA-lhJoZbfZPuNPQUaD9UwcVOYEP6j-Aw49Jab0eht6PQQoOojjf7InL6sWCZ9ToUh9NkIqalaKEEE0zxCr7-C1ylJcfabM14Tweoc6zQ-Q5yOZWScXwoBqjersm_37963IM_-H4v-C_0Jbpt
CitedBy_id crossref_primary_10_1002_pmic_200700957
crossref_primary_10_2217_pgs_12_116
crossref_primary_10_1093_nar_gku814
crossref_primary_10_1155_2012_937506
crossref_primary_10_1016_j_semcdb_2016_08_012
crossref_primary_10_1038_s41419_019_1882_9
crossref_primary_10_1158_0008_5472_CAN_08_4573
crossref_primary_10_1038_srep37635
crossref_primary_10_1186_1471_2407_9_201
crossref_primary_10_1007_s11670_011_0092_5
crossref_primary_10_1007_s00432_014_1858_1
crossref_primary_10_1038_onc_2017_356
crossref_primary_10_1016_j_bbrc_2009_12_105
crossref_primary_10_1016_j_compbiomed_2023_107406
crossref_primary_10_1038_ctg_2014_2
crossref_primary_10_1515_hsz_2014_0254
crossref_primary_10_1016_j_oraloncology_2007_02_009
crossref_primary_10_1016_S2225_4110_16_30116_X
crossref_primary_10_1016_j_bgm_2014_02_002
crossref_primary_10_1186_1477_7827_9_106
crossref_primary_10_1186_1476_4598_9_271
Cites_doi 10.1055/s-0037-1616232
10.1016/0166-2236(88)90182-8
10.1016/0006-8993(86)90872-3
10.1159/000111951
10.1159/000055086
10.1055/s-0037-1615920
10.1159/000469153
10.1016/S0021-9258(17)32540-1
10.1016/S0021-9258(18)94159-1
10.2174/1381612043453559
10.1074/jbc.M310964200
10.1016/0092-8674(80)90112-9
10.1016/S0021-9258(18)53753-4
10.1055/s-2007-994920
10.1177/172460080001500113
10.1016/S0021-9258(17)44476-0
10.1016/S0049-3848(01)00288-2
10.1073/pnas.92.3.895
10.1111/j.1699-0463.1999.tb01534.x
10.1160/TH03-12-0784
10.1007/s000180050497
10.2174/1381612033454621
10.3109/10409239709082573
10.1093/clinchem/48.8.1288
10.1055/s-2007-999018
10.1016/0003-9861(87)90028-2
10.1038/bjc.1998.154
10.1002/jcp.1041170314
10.1023/A:1006115218786
10.1126/science.1067431
ContentType Journal Article
Copyright Copyright National Library of Medicine - MEDLINE Abstracts 2006
Copyright © 2006 Candia et al; licensee BioMed Central Ltd. 2006 Candia et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Copyright National Library of Medicine - MEDLINE Abstracts 2006
– notice: Copyright © 2006 Candia et al; licensee BioMed Central Ltd. 2006 Candia et al; licensee BioMed Central Ltd.
DBID NPM
AAYXX
CITATION
K9.
7X8
5PM
DOA
DOI 10.1186/1475-2867-6-16
DatabaseName PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1475-2867
EndPage 16
ExternalDocumentID oai_doaj_org_article_9ee6ebf8bec14cd19531002fa206dd72
oai_biomedcentral_com_1475_2867_6_16
1643942421
10_1186_1475_2867_6_16
16737540
Genre Journal Article
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R01 HL063291
GroupedDBID ---
-56
-5G
-A0
-BR
0R~
29B
2VQ
2WC
4.4
53G
5GY
5VS
6J9
7X7
AAFWJ
AAJSJ
ABDBF
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BFQNJ
BMC
C1A
C24
C6C
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FRP
GROUPED_DOAJ
GX1
H13
HYE
IAO
IHR
IPNFZ
ISR
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
W2D
WOQ
WOW
XSB
~8M
AAYXX
CITATION
K9.
7X8
ABVAZ
AFGXO
AFNRJ
5PM
ID FETCH-LOGICAL-b539t-1870ef6a318aafb18d453d37dd8e8c3d42be33a3f2de5397bcd39482ca20b7473
IEDL.DBID RPM
ISSN 1475-2867
IngestDate Tue Oct 22 15:05:25 EDT 2024
Tue Sep 17 21:24:58 EDT 2024
Wed May 22 07:13:16 EDT 2024
Fri Oct 25 01:26:34 EDT 2024
Thu Oct 10 15:52:50 EDT 2024
Thu Nov 21 21:55:05 EST 2024
Sat Sep 28 07:41:55 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b539t-1870ef6a318aafb18d453d37dd8e8c3d42be33a3f2de5397bcd39482ca20b7473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1501059/
PMID 16737540
PQID 235091375
PQPubID 42568
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_9ee6ebf8bec14cd19531002fa206dd72
pubmedcentral_primary_oai_pubmedcentral_nih_gov_1501059
biomedcentral_primary_oai_biomedcentral_com_1475_2867_6_16
proquest_miscellaneous_68626283
proquest_journals_235091375
crossref_primary_10_1186_1475_2867_6_16
pubmed_primary_16737540
PublicationCentury 2000
PublicationDate 2006-05-31
PublicationDateYYYYMMDD 2006-05-31
PublicationDate_xml – month: 05
  year: 2006
  text: 2006-05-31
  day: 31
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Cancer cell international
PublicationTitleAlternate Cancer Cell Int
PublicationYear 2006
Publisher National Library of Medicine - MEDLINE Abstracts
BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: National Library of Medicine - MEDLINE Abstracts
– name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 12004111 - Science. 2002 May 10;296(5570):1046-9
12142386 - Clin Chem. 2002 Aug;48(8):1288-95
3813534 - Arch Biochem Biophys. 1987 Jan;252(1):237-44
7846074 - Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):895-9
10066075 - Breast Cancer Res Treat. 1998;52(1-3):99-111
14754404 - Curr Pharm Des. 2004;10(1):39-49
11555589 - Clin Cancer Res. 2001 Sep;7(9):2757-64
1884381 - Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s
11457471 - Thromb Res. 2001 Jul 15;103(2):135-42
10763144 - Int J Biol Markers. 2000 Jan-Mar;15(1):70-2
14983218 - Thromb Haemost. 2004 Mar;91(3):438-49
3730865 - Brain Res. 1986 Jul 9;377(2):298-304
2521625 - J Biol Chem. 1989 Feb 5;264(4):2185-8
3771529 - J Biol Chem. 1986 Oct 25;261(30):14184-90
8006028 - J Biol Chem. 1994 Jun 24;269(25):17199-205
11487024 - Thromb Haemost. 2001 Jul;86(1):346-55
3139400 - Enzyme. 1988;40(2-3):113-21
10605712 - Thromb Haemost. 1999 Aug;82(2):259-70
8429047 - J Biol Chem. 1993 Feb 15;268(5):3720-7
6157479 - Cell. 1980 Aug;21(1):37-45
8836012 - Semin Thromb Hemost. 1996;22(3):267-71
6317700 - J Cell Physiol. 1983 Dec;117(3):385-96
9239493 - Crit Rev Biochem Mol Biol. 1997;32(3):175-253
15138609 - Int J Mol Med. 2004 Jun;13(6):759-66
3371230 - Dev Neurosci. 1988;10(1):17-24
12871067 - Curr Pharm Des. 2003;9(19):1545-64
9528837 - Br J Cancer. 1998 Mar;77(6):932-40
10357086 - Semin Thromb Hemost. 1999;25(2):183-97
1288365 - Ann N Y Acad Sci. 1992 Dec 31;674:228-36
12941819 - Cancer Res. 2003 Aug 15;63(16):4945-51
6885787 - J Biol Chem. 1983 Sep 10;258(17):10439-44
11455216 - Onkologie. 2001 Jun;24(3):238-44
14699093 - J Biol Chem. 2004 Mar 12;279(11):10346-56
14758095 - Breast Cancer Res Treat. 2004 Feb;83(3):249-89
10190288 - APMIS. 1999 Jan;107(1):120-7
2471310 - Trends Neurosci. 1988 Dec;11(12):541-4
10949579 - Cell Mol Life Sci. 2000 Jan 20;57(1):25-40
JT Price (152_CR1) 1997; 32
PJ Vaughan (152_CR15) 1993; 268
MP Look (152_CR26) 2000; 15
AD Zurn (152_CR17) 1988; 10
RW Stephens (152_CR9) 1998; 52
MK Durand (152_CR28) 2004; 91
DD Cunningham (152_CR33) 1992
A Knoop (152_CR8) 1998; 77
EW Howard (152_CR22) 1986
D Monard (152_CR34) 1988; 11
NK Kim (152_CR12) 2001; 103 (2)
N Harbeck (152_CR24) 2001; 7
SR Stone (152_CR14) 1987; 252
V Ellis (152_CR5) 1989; 264
RWBJB Scott (152_CR23) 1983; 258
K Dano (152_CR2) 1999; 107
P Rossignol (152_CR35) 2004; 279
FM Donovan (152_CR20) 1994; 269
JB Baker (152_CR37) 1980; 21
BS Wiseman (152_CR36) 2002; 296
LA Liotta (152_CR7) 1991; 51
MJ Duffy (152_CR30) 2004; 10(1)
J Chorostowska-Wynimko (152_CR32) 2004; 13(6)
VA Carroll (152_CR3) 1999; 25
EK Kruithof (152_CR13) 1988; 40
S Stefansson (152_CR29) 2003; 9
PA Andreasen (152_CR4) 2000; 57
MLG Lacroix (152_CR27) 2004
D Collen (152_CR10) 1999; 82
R Castello (152_CR21) 2002; 48
M Buchholz (152_CR31) 2003; 63
BW Festoff (152_CR18) 1996; 22
MS Pepper (152_CR6) 2001; 86
J Lindner (152_CR19) 1986; 377
DJ Knauer (152_CR11) 1983; 117
LJ Houenou (152_CR16) 1995; 92
N Harbeck (152_CR25) 2001; 24
References_xml – volume: 86
  start-page: 346
  year: 2001
  ident: 152_CR6
  publication-title: Thrombosis & Haemostasis
  doi: 10.1055/s-0037-1616232
  contributor:
    fullname: MS Pepper
– volume: 11
  start-page: 541
  issue: 12
  year: 1988
  ident: 152_CR34
  publication-title: Trends in neurosciences
  doi: 10.1016/0166-2236(88)90182-8
  contributor:
    fullname: D Monard
– start-page: 249
  volume-title: Breast Cancer Research and Treatment
  year: 2004
  ident: 152_CR27
  contributor:
    fullname: MLG Lacroix
– volume: 377
  start-page: 298
  issue: 2
  year: 1986
  ident: 152_CR19
  publication-title: Brain Research
  doi: 10.1016/0006-8993(86)90872-3
  contributor:
    fullname: J Lindner
– volume: 10
  start-page: 17
  issue: 1
  year: 1988
  ident: 152_CR17
  publication-title: Developmental Neuroscience
  doi: 10.1159/000111951
  contributor:
    fullname: AD Zurn
– volume: 24
  start-page: 238
  issue: 3
  year: 2001
  ident: 152_CR25
  publication-title: Onkologie
  doi: 10.1159/000055086
  contributor:
    fullname: N Harbeck
– volume: 82
  start-page: 259
  year: 1999
  ident: 152_CR10
  publication-title: Thrombosis & Haemostasis
  doi: 10.1055/s-0037-1615920
  contributor:
    fullname: D Collen
– volume: 40
  start-page: 113
  issue: 2-3
  year: 1988
  ident: 152_CR13
  publication-title: Enzyme
  doi: 10.1159/000469153
  contributor:
    fullname: EK Kruithof
– volume: 269
  start-page: 17199
  issue: 25
  year: 1994
  ident: 152_CR20
  publication-title: Journal of Biological Chemistry
  doi: 10.1016/S0021-9258(17)32540-1
  contributor:
    fullname: FM Donovan
– volume: 264
  start-page: 2185
  issue: 4
  year: 1989
  ident: 152_CR5
  publication-title: Journal of Biological Chemistry
  doi: 10.1016/S0021-9258(18)94159-1
  contributor:
    fullname: V Ellis
– start-page: 14184
  volume-title: Journal of Biological Chemistry
  year: 1986
  ident: 152_CR22
  contributor:
    fullname: EW Howard
– volume: 10(1)
  start-page: 39
  year: 2004
  ident: 152_CR30
  publication-title: Current pharmaceutical design
  doi: 10.2174/1381612043453559
  contributor:
    fullname: MJ Duffy
– volume: 279
  start-page: 10346
  issue: 11
  year: 2004
  ident: 152_CR35
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M310964200
  contributor:
    fullname: P Rossignol
– volume: 21
  start-page: 37
  issue: 1
  year: 1980
  ident: 152_CR37
  publication-title: Cell
  doi: 10.1016/0092-8674(80)90112-9
  contributor:
    fullname: JB Baker
– volume: 268
  start-page: 3720
  issue: 5
  year: 1993
  ident: 152_CR15
  publication-title: Journal of Biological Chemistry
  doi: 10.1016/S0021-9258(18)53753-4
  contributor:
    fullname: PJ Vaughan
– volume: 7
  start-page: 2757
  issue: 9
  year: 2001
  ident: 152_CR24
  publication-title: Clinical Cancer Research
  contributor:
    fullname: N Harbeck
– volume: 25
  start-page: 183
  issue: 2
  year: 1999
  ident: 152_CR3
  publication-title: Seminars in Thrombosis & Hemostasis
  doi: 10.1055/s-2007-994920
  contributor:
    fullname: VA Carroll
– volume: 15
  start-page: 70
  issue: 1
  year: 2000
  ident: 152_CR26
  publication-title: International Journal of Biological Markers
  doi: 10.1177/172460080001500113
  contributor:
    fullname: MP Look
– volume: 258
  start-page: 10439
  year: 1983
  ident: 152_CR23
  publication-title: Journal of Biological Chemistry
  doi: 10.1016/S0021-9258(17)44476-0
  contributor:
    fullname: RWBJB Scott
– volume: 103 (2)
  start-page: 135
  year: 2001
  ident: 152_CR12
  publication-title: Thrombosis Research
  doi: 10.1016/S0049-3848(01)00288-2
  contributor:
    fullname: NK Kim
– volume: 92
  start-page: 895
  issue: 3
  year: 1995
  ident: 152_CR16
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.92.3.895
  contributor:
    fullname: LJ Houenou
– volume: 107
  start-page: 120
  issue: 1
  year: 1999
  ident: 152_CR2
  publication-title: APMIS
  doi: 10.1111/j.1699-0463.1999.tb01534.x
  contributor:
    fullname: K Dano
– volume: 51
  start-page: 5054s
  issue: 18 Suppl
  year: 1991
  ident: 152_CR7
  publication-title: Cancer Research
  contributor:
    fullname: LA Liotta
– start-page: 228
  volume-title: Annals of the New York Academy of Sciences
  year: 1992
  ident: 152_CR33
  contributor:
    fullname: DD Cunningham
– volume: 91
  start-page: 438
  issue: 3
  year: 2004
  ident: 152_CR28
  publication-title: Thromb Haemost
  doi: 10.1160/TH03-12-0784
  contributor:
    fullname: MK Durand
– volume: 13(6)
  start-page: 759
  year: 2004
  ident: 152_CR32
  publication-title: International journal of molecular medicine
  contributor:
    fullname: J Chorostowska-Wynimko
– volume: 57
  start-page: 25
  issue: 1
  year: 2000
  ident: 152_CR4
  publication-title: Cellular & Molecular Life Sciences
  doi: 10.1007/s000180050497
  contributor:
    fullname: PA Andreasen
– volume: 9
  start-page: 1545
  issue: 19
  year: 2003
  ident: 152_CR29
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612033454621
  contributor:
    fullname: S Stefansson
– volume: 32
  start-page: 175
  issue: 3
  year: 1997
  ident: 152_CR1
  publication-title: Critical Reviews in Biochemistry & Molecular Biology
  doi: 10.3109/10409239709082573
  contributor:
    fullname: JT Price
– volume: 63
  start-page: 4945
  issue: 16
  year: 2003
  ident: 152_CR31
  publication-title: Cancer Research
  contributor:
    fullname: M Buchholz
– volume: 48
  start-page: 1288
  issue: 8
  year: 2002
  ident: 152_CR21
  publication-title: Clinical Chemistry
  doi: 10.1093/clinchem/48.8.1288
  contributor:
    fullname: R Castello
– volume: 22
  start-page: 267
  issue: 3
  year: 1996
  ident: 152_CR18
  publication-title: Seminars in Thrombosis & Hemostasis
  doi: 10.1055/s-2007-999018
  contributor:
    fullname: BW Festoff
– volume: 252
  start-page: 237
  issue: 1
  year: 1987
  ident: 152_CR14
  publication-title: Archives of Biochemistry & Biophysics
  doi: 10.1016/0003-9861(87)90028-2
  contributor:
    fullname: SR Stone
– volume: 77
  start-page: 932
  issue: 6
  year: 1998
  ident: 152_CR8
  publication-title: British Journal of Cancer
  doi: 10.1038/bjc.1998.154
  contributor:
    fullname: A Knoop
– volume: 117
  start-page: 385
  issue: 3
  year: 1983
  ident: 152_CR11
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.1041170314
  contributor:
    fullname: DJ Knauer
– volume: 52
  start-page: 99
  issue: 1-3
  year: 1998
  ident: 152_CR9
  publication-title: Breast Cancer Research & Treatment
  doi: 10.1023/A:1006115218786
  contributor:
    fullname: RW Stephens
– volume: 296
  start-page: 1046
  issue: 5570
  year: 2002
  ident: 152_CR36
  publication-title: Science
  doi: 10.1126/science.1067431
  contributor:
    fullname: BS Wiseman
SSID ssj0017860
Score 1.8800023
Snippet Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of...
BACKGROUND: Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation...
BACKGROUNDUrokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the degradation of...
Abstract Background Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role in human breast cancer metastasis by mediating the...
SourceID doaj
pubmedcentral
biomedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 16
SubjectTerms Breast cancer
Primary Research
SummonAdditionalLinks – databaseName: BiomedCentral
  dbid: RBZ
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB0VqkpcSqHQBij4UAkuUdexYzvcoAVx4gBUQlwsJ-OoK1WhYnel9t93JskuBDggcY3jyJkP-Y1n_AbgqybUHZBp9gkTpUx4l7qCjzkqW7usouG2N-DZpT2_dj9OmCbn4PkMvnTmm9Q2TzNH_mxSaZbgLQUMmm354vhmkS-wrrsPPH-3p2d8Ov_Rvfbfg-2oZe1_Dmo-rph8sAWdrr588R_gfQ8zxVFnF2vwJjbr8K5rPPnvIzBJ_pQTM4KpMJtUivi3r4htxHgi2hx6RDFuRNvET5Rcuz4VFdvI3Qb8PD25-n6W9o0U0jJXxZT0YEexNoH8N4S6lA51rlBZRBddpVBnZVQqqDrDSBNsWaEqNKkqZKOS4g21CcvNbRM_gxi5skYstDWy1hJDMcop4imCxTxQLBkTOBzI1__pSDM801gPR8ijPMvHs3y88dIksD9XxmJeG6Q48-TNY9bV4OvtAxK-733OFzGaWNaOzFTqCjlhyISzNf2VQbRZAttzTfvecyc-UwyhlM0T2FuMkstxHiU08XY28XypxhAsS-BTZxX3i-WuP4SBE7ADexmsczjSjH-1pN4EzBnqbr1Gftuw0p0QcXHDDixP72bxCyxNcLbbust_zgkPIg
  priority: 500
  providerName: BioMedCentral
– databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB3RlZC4VLR8hQXqAxKnaJM4sR1uFHa1Jy6AxM1yMo5YqUqrJivRf89MnA2kReqlVztOnPFM_CYzfgPwPifU7ZBp9gkTxUx4F5uSf3PUujFZTd1DbcDtN_31p_myZpqcqdQX54QFeuAguFXpvfJVY-hZaV4jR32YNbRxWaIQdfj6JurgTI3xA23C-eBcF3FmlB7pGlOjVlNbrGKucj47534x254GFv__Qc_bGZT_bEmbp3A8YknxKbzDCTzy7Sk8DtUlb54BM-H3HH0RzHfZxqnwv8e011bsOjEEyj2KXSuGSn2i4gT1XtSsCNfP4cdm_f3zNh6rJcRVIcuehK0T3yhHRupcU6UG80Ki1IjGm1pinlVeSiebDD0N0FWNssxpPUiSFTkV8gUs2svWvwKRmKpBLHOt0iZP0ZVJQW5N6TQWjhxGH8HHmdDsVWDGsMxVPe8hs7EsccsSt8qmKoIPBwlP4wZPxKg7V57zAszuPjSQfthRP-x9-hHB8rB8djTPzmaScZLURQRnUy_ZFQdLXOsv953lkzOKsFcEL8NS_50sl_YhoBuBninBbJ7znnb3a2DuJvTNePb1Q7zYEp6E30GcyfAGFv313r-Fow737wZb-AMEXA0b
  priority: 102
  providerName: Directory of Open Access Journals
Title Protease nexin-1 expression is altered in human breast cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/16737540
https://www.proquest.com/docview/235091375
https://search.proquest.com/docview/68626283
http://dx.doi.org/10.1186/1475-2867-6-16
https://pubmed.ncbi.nlm.nih.gov/PMC1501059
https://doaj.org/article/9ee6ebf8bec14cd19531002fa206dd72
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6xlZC4ICivUGh9QOKUbhwntsONvtRLEeIhIS6WHTt0pTZb7UOCf8-M4xQCnLjkEMeRM56Jv_GMvwF4VSHqtp5o9hET5UR4l-uGtjla1emyxeZYG_D8o3r3RZ-cEk1OPZ6FiUn7rVsc9lfXh_3iMuZW3ly38zFPbP7-4hhBDMGC-QxmiA1HFz2FDpSWRWJn5FrOeaXqvNT4O5A5jwWLqDJL3OyYnHC_mixMkb__X6Dzz9zJ3xajswdwP6FI9nYY7UO4E_pduDvUlfzxCIgDf0NxF0ZMl33OWfieEl57tlizGCIPni16Fmv0MUep6RvWkgqsHsPns9NPx-d5qpOQu1o0GxSzKkInLZqntZ3j2le18EJ5r4Nuha9KF4Swoit9wA7KtV40Fc6ELQuH7oR4Ajv9sg_PgBXadd43lZK8q7i3TVGjQ9NY5WuLrmLI4M1EaOZm4MQwxFI9bUGDMSR8Q8I30nCZwetRwrf9og-i5V9PHtEETN4ebyxX30zSBNOEIIPrNGohr1pP8UDik-3wq6T3qsxgb5w-kwxzbUpBCAkVIIOD21a0KAqT2D4st2tDZ2Ykoq4Mng5T_WuwSXUyUBMlmIxz2oIqHDm7k8o-_--ee3Bv2P2hxIUXsLNZbcNLmK39dj_uI-D1w9HX_WgLPwHnaAzc
link.rule.ids 108,230,315,729,782,786,866,887,2106,24946,27933,27934,53800,53802,75821,75822
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9UwDLfYEIIL45uywXJA4tS9pmmTlBsbmx5im5AYErcobdLxpC1veh8S_PfYaTtW4LRr3VRpbLc_x87PAG8LRN3WEc0-YqKUCO9SXdE2R6NanTcojr0Bp1_V6Xf98ZBocsrhLEws2m_q2V64uNwLsx-xtvLqspkMdWKTLycHCGIIFkw24C76a5YNQXqfPFBaZj0_I9dywgtVprnGD4JMeWxZRL1Z4nbH6Iz7xejXFBn8_wc7_66evPE7Otq65Ys8goc9_mQfOvFjuOPDE7jXdaT89RSIPX9FGRtGHJkh5cz_7EtlA5stWUyue8dmgcXufqymovYVa8h4Fs_g29Hh2cE07TsspHUpqhUqSGW-lRYd29q25toVpXBCOae9boQr8toLYUWbO48DVN04URWoQ5tnNQYi4jlshnnwL4Flum6dqwoleVtwZ6usxFCossqVFoNMn8D70WKbq45NwxC_9ViCrmZIaYaUZqThMoF3g2aux8XoRct_7twnxY2eHi_MF-emX3pTeS993Wq0X140jjKJxETb4ltJ51SewPagdtO79NLkgrAVGk4Cu9dS9EVKsNjg5-ulodM2EvFaAi86E_kz2d7kElAj4xnNcyxBm4ls372NvLr1yF24Pz07OTbHn04_b8ODbg-Jyh92YHO1WPvXsLF06zfRh34Ded8gVQ
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlAvvKGhQH1A4pQmjhPb4QZtV0VAVQmQuFl27MBKbXa1Dwn-PTNOdiHACa6xHTmemfgbz_gbgOclom7riWYfMVFKhHeprumYo1GtLhpsjrUBzz6o88_65JRocralvmLSfuOmR93l1VE3_RpzK-dXTbbJE8su3h8jiCFYkM19m-3AdbTZvNg46kMAQWmZDxyNXMuMl6pKC40_BZnyWLaI6rPEI4_RPffL0fYUWfz_Bj1_z6D8ZUua3P6Pj7kDtwYcyl71Xe7CtdDdgxt9Zcrv94FY9FcUuWHEldmlnIVvQ8psx6ZLFoPswbNpx2KVP-YouX3FGlKixQP4NDn9eHyWDpUWUleJeoWCUnlopUUDt7Z1XPuyEl4o73XQjfBl4YIQVrSFDzhAucaLukRZ2iJ36JCIh7DbzbqwDyzXrvW-LpXkbcm9rfMKXaLaKl9ZdDZDAi9HC27mPauGIZ7rcQuanCHBGRKckYbLBF5spLMdF70YLf_o-ZqEN3p7fDBbfDHD8ps6BBlcq1GPedl4iigSI22LXyW9V0UCBxvRm8G0l6YQhLFQeRI43LaiTVKgxXZhtl4aunUjEbcl8KhXk5-THdQuATVSoNE8xy2oN5H1e9CTx_888hBuXpxMzLs3528PYK8_SqIsiCewu1qsw1PYWfr1s2hGPwB83SLV
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protease+nexin-1+expression+is+altered+in+human+breast+cancer&rft.jtitle=Cancer+cell+international&rft.au=Candia%2C+Britny+J&rft.au=Hines%2C+William+C&rft.au=Heaphy%2C+Christopher+M&rft.au=Griffith%2C+Jeffrey+K&rft.date=2006-05-31&rft.pub=National+Library+of+Medicine+-+MEDLINE+Abstracts&rft.eissn=1475-2867&rft.volume=6&rft.spage=16&rft_id=info:doi/10.1186%2F1475-2867-6-16&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=1643942421
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon